Effect of Erythropoietin on SOFA Score, Glasgow Coma Scale and Mortality in Traumatic Brain Injury Patients: a Randomized-double-blind Controlled Trial

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2024 Jul 11

PMID 38989196

Authors

Seyyed Javad Boskabadi

Fatemeh Heydari

Farhad Mohammadnejad

Afshin Gholipour Baradari

Mahmood Moosazadeh

Ayat Dashti

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies suggest that erythropoietin has an anti-inflammatory effect on the central nervous system. The authors aimed to investigate the effect of erythropoietin on Glasgow Coma Scale (GCS), Sequential Organ Failure Assessment (SOFA) scores, and the mortality rate of traumatic brain injury (TBI) patients.

Methods: Sixty-eight patients with available inclusion criteria were randomly allocated to the control or intervention groups. In the intervention group, erythropoietin (4000 units) was administrated on days 1, 3, and 5. In the control group, normal saline on the same days was used. The primary outcomes were the GCS and SOFA score changes during the intervention. The secondary outcomes were the ventilation period during the first 2 weeks and the 3-month mortality rate.

Results: Erythropoietin administration significantly affected SOFA score over time (=0.008), but no significant effect on the GCS, and duration of ventilation between the two groups was observed. Finally, erythropoietin had no significant effect on the three-month mortality (23.5% vs. 38.2% in the erythropoietin and control group, respectively). However, the mortality rate in the intervention group was lower than in the control group.

Conclusion: Our finding showed that erythropoietin administration in TBI may improve SOFA score. Therefore, erythropoietin may have beneficial effects on early morbidity and clinical improvement in TBI patients.

References

Osler T, Cook A, Glance L, Lecky F, Bouamra O, Garrett M . The differential mortality of Glasgow Coma Score in patients with and without head injury. Injury. 2016; 47(9):1879-85. DOI: 10.1016/j.injury.2016.04.016. View

Moradi Z, Maali A, Shad J, Farasat A, Kouchaki R, Moghadami M . Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach. Indian J Hematol Blood Transfus. 2020; 36(1):26-36. PMC: 7042474. DOI: 10.1007/s12288-019-01170-1. View

Gantner D, Bailey M, Presneill J, French C, Nichol A, Little L . Erythropoietin to Reduce Mortality in Traumatic Brain Injury: A Post-hoc Dose-effect Analysis. Ann Surg. 2017; 267(3):585-589. DOI: 10.1097/SLA.0000000000002142. View

Liu W, Chu D, Chan H, Li S, Liu C, Yang C . Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis. Clin Exp Pharmacol Physiol. 2016; 43(10):875-82. DOI: 10.1111/1440-1681.12618. View

Shiehmorteza M, Ahmadi A, Abdollahi M, Nayebpour M, Mohammadi M, Hamishehkar H . Recombinant human erythropoietin reduces plasminogen activator inhibitor and ameliorates pro-inflammatory responses following trauma. Daru. 2012; 19(2):159-65. PMC: 3232093. View

Luchette F, Pasquale M, Fabian T, Langholff W, Wolfson M . A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study. Am J Surg. 2011; 203(4):508-16. DOI: 10.1016/j.amjsurg.2011.08.006. View

Mammis A, McIntosh T, Maniker A . Erythropoietin as a neuroprotective agent in traumatic brain injury Review. Surg Neurol. 2008; 71(5):527-31. DOI: 10.1016/j.surneu.2008.02.040. View

Carmichael S . Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol. 2006; 59(5):735-42. DOI: 10.1002/ana.20845. View

Thapa K, Khan H, Singh T, Kaur A . Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets. J Mol Neurosci. 2021; 71(9):1725-1742. DOI: 10.1007/s12031-021-01841-7. View

10.

Nirula R, Diaz-Arrastia R, Brasel K, Weigelt J, Waxman K . Safety and efficacy of erythropoietin in traumatic brain injury patients: a pilot randomized trial. Crit Care Res Pract. 2010; 2010. PMC: 2951080. DOI: 10.1155/2010/209848. View

11.

Frohlich M, Wafaisade A, Mansuri A, Koenen P, Probst C, Maegele M . Which score should be used for posttraumatic multiple organ failure? - Comparison of the MODS, Denver- and SOFA- Scores. Scand J Trauma Resusc Emerg Med. 2016; 24(1):130. PMC: 5094147. DOI: 10.1186/s13049-016-0321-5. View

12.

Villa P, van Beek J, Larsen A, Gerwien J, Christensen S, Cerami A . Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab. 2006; 27(3):552-63. DOI: 10.1038/sj.jcbfm.9600370. View

13.

Liu M, Wang A, Chen Y, Zhao G, Jiang Z, Wang X . Efficacy and safety of erythropoietin for traumatic brain injury. BMC Neurol. 2020; 20(1):399. PMC: 7604969. DOI: 10.1186/s12883-020-01958-z. View

14.

Reichel C, Erceg D, Lorenc B, Scheiblhofer V, Farmer L, Zanitzer K . Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol. Drug Test Anal. 2021; 15(2):163-172. DOI: 10.1002/dta.2989. View

15.

Cerami A, Brines M, Ghezzi P, Cerami C, Itri L . Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant. 2002; 17 Suppl 1:8-12. DOI: 10.1093/ndt/17.suppl_1.8. View

16.

AslRoosta H, Yaghobee S, Akbari S, Kanounisabet N . The effects of topical erythropoietin on non-surgical treatment of periodontitis: a preliminary study. BMC Oral Health. 2021; 21(1):240. PMC: 8101234. DOI: 10.1186/s12903-021-01607-y. View

17.

MacQueen R, Fisher P, Williams D . A qualitative investigation of masculine identity after traumatic brain injury. Neuropsychol Rehabil. 2018; 30(2):298-314. DOI: 10.1080/09602011.2018.1466714. View

18.

Merelli A, Czornyj L, Lazarowski A . Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases. Int J Neurosci. 2014; 125(11):793-7. DOI: 10.3109/00207454.2014.989321. View

19.

Summers C, Ivins B, Schwab K . Traumatic brain injury in the United States: an epidemiologic overview. Mt Sinai J Med. 2009; 76(2):105-10. DOI: 10.1002/msj.20100. View

20.

Yilmaz T, Kaptanoglu E . Current and future medical therapeutic strategies for the functional repair of spinal cord injury. World J Orthop. 2015; 6(1):42-55. PMC: 4303789. DOI: 10.5312/wjo.v6.i1.42. View